Antiviral therapy in HCV decompensated cirrhosis: To treat or not to treat?

Journal of Hepatology

Volumn 46, Issue 2, 2007, Pages 185-188

  Navasa, Miquel ^a   Forns, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN;

COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAINTENANCE THERAPY; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 33845658184     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.11.001     Document Type: Editorial

References (16)

1. Crippin J.S., McCashland T., Terrault N., Sheiner P., and Charlton M.R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 8 (2002) 350-355
2. Everson G.T., Trotter J., Forman L., Kugelmas M., Halprin A., Fey B., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 (2005) 255-262
3. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la M.M., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39 (2003) 389-396
4. Thomas R.M., Brems J.J., Guzman-Hartman G., Yong S., Cavaliere P., and Van Thiel D.H. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 9 (2003) 905-915
5. Hoofnagle J.H., Di Bisceglie A.M., Waggoner J.G., and Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104 (1993) 1116-1121
6. Fontana R.J., Keeffe E.B., Carey W., Fried M., Reddy R., Kowdley K.V., et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 8 (2002) 433-439
7. Manolakopoulos S., Karatapanis S., Elefsiniotis J., Mathou N., Vlachogiannakos J., Iliadou E., et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 99 (2004) 57-63
8. Perrillo R.P., Wright T., Rakela J., Levy G., Schiff E., Gish R., et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
9. Yao F.Y., Terrault N.A., Freise C., Maslow L., and Bass N.M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34 (2001) 411-416
10. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
11. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
12. Yim H.J., and Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 2 Suppl. 1 (2006) S173-S181
13. Iacobellis A., Siciliano M., Perri F., Annicchiarico B.E., Leandro G., Caruso N., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. J Hepatol 46 (2007) 206-212
14. Rincon D., Ripoll C., Iacono O.L., Salcedo M., Catalina M.V., Alvarez E., et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 101 10 (2006) 2269-2274
15. Afdhal N., Freilish B., Levine R., et al. Colchicine versus PEG-Intron long term (COPILOT) trial: Interim analysis of clinical outcomes at year 2. Hepatology 40 (2004) 239A (Abstract)
16. Wong F., Bernardi M., Balk R., Christman B., Moreau R., Garcia-Tsao G., et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 54 (2005) 718-725